CD123 ‐targeting immunotherapeutic approaches in acute myeloid leukaemia
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Alexandra Dreyzin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Interleukin-3 Receptor alpha Subunit, Immunotherapy, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Baldrick's Foundation, NCI NIH HHS, National Cancer Institute - NIH K12 Scholars.
Abstract (Originalsprache)
Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with variable anti‐tumour responses and toxicities observed. Here, we review the clinical outcomes of these therapies, including monoclonal antibodies and antibody‐drug conjugates, as well as bispecific T‐cell engager molecules and chimeric antigen receptor (CAR) T cells. We discuss the potential reasons for therapy‐associated toxicity and limited efficacy, including differential antigen expression, the AML microenvironment and patient‐derived T‐cell fitness. To address these challenges, we highlight novel approaches to CD123 targeting currently in preclinical development. Promising new strategies include combination therapies that target CD123 and other known AML‐associated antigens such as CD33 or CLL‐1, NK‐cell‐based cell therapies, and bispecific‐secreting T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Alexandra Dreyzin, Noa G Holtzman
Förderung
- St. Baldrick's Foundation
- NCI NIH HHS
- National Cancer Institute - NIH K12 Scholars
- Alex's Lemonade Stand Foundation for Childhood Cancer
- American Cancer Society
Zitieren
APA
Dreyzin, A., Holtzman, N. G., & Bonifant, C. L. (2025). CD123 ‐targeting immunotherapeutic approaches in acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70019
Vancouver
Dreyzin A, Holtzman NG, Bonifant CL. CD123 ‐targeting immunotherapeutic approaches in acute myeloid leukaemia. British Journal of Haematology. 2025. doi:10.1111/bjh.70019
BibTeX
@article{Dreyzin2025,
author = {Dreyzin, Alexandra and Holtzman, Noa G and Bonifant, Challice L},
title = {CD123 ‐targeting immunotherapeutic approaches in acute myeloid leukaemia},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70019}
}
EUVIMED